Developing Multi-Omic Biomarker Strategies for Assessing Sensitivity of RASTargeting Drugs for More Efficacious Therapies

  • Uncovering the impact of genomics on RAS inhibitor sensitivity
  • Highlighting how transcriptional signatures may affect sensitivity to RAS targeting drugs
  • Predicting RAS sensitivity through proteomic biomarkers and pathway analysis to advance more effective RAS-targeting drugs and combinations